Who are Intravenous Tenecteplase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrinolytic once daily, low-dose tenecteplase intravenous thrombolysis, Fibrinolytic twice daily, TNK-tPA, Intravenous rhTNK-tPA, Low-dose intravenous tenecteplase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-tenecteplase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Intravenous Tenecteplase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Tenecteplase (Intravenous Tenecteplase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Tissue plasminogen activator (tPA). Area: Cardiovascular.

phase 3 Fibrinolytic agent / Tissue plasminogen activator (tPA) Plasminogen / Fibrin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Tenecteplase (Intravenous Tenecteplase) — NHS Greater Glasgow and Clyde. Tenecteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous Tenecteplase TARGET	Intravenous Tenecteplase	NHS Greater Glasgow and Clyde	phase 3	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Fibrinolytic once daily	Fibrinolytic once daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Fibrinolytic twice daily	Fibrinolytic twice daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent	Plasminogen / Fibrin
TNK-tPA	TNK-tPA	Beijing Tiantan Hospital	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Intravenous rhTNK-tPA	Intravenous rhTNK-tPA	Xinqiao Hospital of Chongqing	phase 3	Thrombolytic agent / Fibrinolytic	Plasminogen / Fibrin
Low-dose intravenous tenecteplase	Low-dose intravenous tenecteplase	The George Institute	phase 3	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Tissue plasminogen activator (tPA) class)

Central Hospital, Nancy, France · 1 drug in this class
Genentech, Inc. · 1 drug in this class
Hospital Clinic of Barcelona · 1 drug in this class
NHS Greater Glasgow and Clyde · 1 drug in this class
Southwest Hospital, China · 1 drug in this class
The George Institute · 1 drug in this class
University of Manitoba · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Tenecteplase — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-tenecteplase. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing